01 March 2022 | News
The Oncomine Clinical Research Grant programme aims to fund research furthering understanding of cancer at the genomic level
image credit- shutterstock
As part of its ongoing commitment to support clinical oncology research, US-based Thermo Fisher Scientific is calling for new proposals for its Oncomine Clinical Research Grant. The latest request for submissions from the global scientific community will award funding for molecular profiling research that helps accelerate the use of genomic sequencing in oncology.
The recipients of the grants will each be awarded up to $200,000 in reagents and general funding for independent clinical research proposals that demonstrate excellence in cancer molecular profiling.
Project proposals harnessing the value of next generation sequencing (NGS) in either the context of solid or hematological cancers will be reviewed by independent and internationally recognized experts for scientific rigor and merit. Grant proposals are now being accepted through April 7, 2022.
Since launching the programme in 2020, Thermo Fisher has awarded Oncomine Clinical Research Grants to 16 projects worldwide in support of research in hematology-oncology, immuno-oncology, liquid biopsy, and fusion gene detection. Recipients of the last funding round, which supported clinical research programmes using NGS technology in solid tumors and hematology-oncology applications, included: Myung-shin Kim, The Catholic University of Korea Seoul St. Mary’s Hospital, South Korea; Wolfram Jochum, Kantonsspital St. Gallen, Switzerland; Fernando Lopez-Rios, Hospital Universitario 12 de Octubre, Spain; Tarek Bismar, University of Calgary, Canada.